RxDoctor Payments Data

Jorge Medina, MD

Internal Medicine · Lowell, INNPI 1194762054

Payments from drug & device makers

$1,135in general payments, 2019–2025

Across 43 payments — averaging $26.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$349
  • Johnson & Johnson$207
  • Phathom Pharmaceuticals, Inc.$114
  • AbbVie$114
  • Merck$110
  • Axsome Therapeutics, Inc.$95
  • plus $145 from 6 others

What the payments were for

  • Food & beverage$1,135100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,135 in reported general payments places this provider in the 75th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$112,084
Medicare patients
318
Services billed
1,538

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin158$172,924
MounjaroTirzepatide58$72,360
JanuviaSitagliptin Phosphate46$54,519
EliquisApixaban57$48,602
XareltoRivaroxaban46$45,889
FarxigaDapagliflozin Propanediol27$31,014
Stiolto RespimatTiotropium Br/Olodaterol Hcl28$25,342
Breo ElliptaFluticasone/Vilanterol24$23,815
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog25$19,986
OzempicSemaglutide12$16,271
JanumetSitagliptin Phos/Metformin Hcl12$15,402
Lantus SolostarInsulin Glargine,hum.Rec.Anlog56$13,385
Atorvastatin Calcium669$4,213
Albuterol Sulfate HfaAlbuterol Sulfate176$3,554
Levothyroxine Sodium287$2,844

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Stiolto Respimat$16$198,266186 claims
MerckJanuvia, Janumet$110$69,92158 claims
PfizerEliquis$24$48,60257 claims
Johnson & JohnsonXarelto$207$45,88946 claims
AstraZenecaFarxiga, Symbicort$56$33,78839 claims
GSKBreo Ellipta$11$23,81524 claims
Novo NordiskOzempic$349$16,27112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in Lowell

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →